Vanguard Group
TAK icon

Vanguard Group’s Takeda Pharmaceutical TAK Stock Holding History

Vanguard Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.59M Hold
101,870
– – ﹤0.01% 3635
2025
Q3 		$1.49M Hold
101,870
– – ﹤0.01% 3664
2025
Q2 		$1.57M Hold
101,870
– – ﹤0.01% 3609
2025
Q1 		$1.51M Hold
101,870
– – ﹤0.01% 3580
2024
Q4 		$1.35M Sell
101,870
-407
-0.4% -$5.59K ﹤0.01% 3669
2024
Q3 		$1.45M Hold
102,277
– – ﹤0.01% 3656
2024
Q2 		$1.32M Buy
102,277
+45,396
+80% +$601K ﹤0.01% 3699
2024
Q1 		$790K Hold
56,881
– – ﹤0.01% 3887
2023
Q4 		$812K Hold
56,881
– – ﹤0.01% 3895
2023
Q3 		$880K Sell
56,881
-83,354
-59% -$1.29M ﹤0.01% 3881
2023
Q2 		$2.2M Sell
140,235
-4,954
-3% -$81.2K ﹤0.01% 3622
2023
Q1 		$2.39M Sell
145,189
-56,220
-28% -$896K ﹤0.01% 3610
2022
Q4 		$3.14M Sell
201,409
-55,095
-21% -$770K ﹤0.01% 3502
2022
Q3 		$3.33M Sell
256,504
-536,773
-68% -$7.46M ﹤0.01% 3527
2022
Q2 		$11.1M Sell
793,277
-608,275
-43% -$8.68M ﹤0.01% 2938
2022
Q1 		$20.1M Sell
1,401,552
-335,379
-19% -$4.92M ﹤0.01% 2775
2021
Q4 		$23.7M Sell
1,736,931
-256,677
-13% -$3.6M ﹤0.01% 2752
2021
Q3 		$32.7M Sell
1,993,608
-502,534
-20% -$8.44M ﹤0.01% 2600
2021
Q2 		$42M Sell
2,496,142
-138,985
-5% -$2.37M ﹤0.01% 2465
2021
Q1 		$48.1M Sell
2,635,127
-389,641
-13% -$7.01M ﹤0.01% 2338
2020
Q4 		$55.1M Sell
3,024,768
-506,824
-14% -$8.89M ﹤0.01% 2144
2020
Q3 		$63M Sell
3,531,592
-1,006,479
-22% -$18.3M ﹤0.01% 1896
2020
Q2 		$81.4M Sell
4,538,071
-1,139,115
-20% -$20.4M ﹤0.01% 1770
2020
Q1 		$86.2M Sell
5,677,186
-300,018
-5% -$5.44M ﹤0.01% 1611
2019
Q4 		$118M Sell
5,977,204
-176,639
-3% -$3.38M ﹤0.01% 1674
2019
Q3 		$106M Sell
6,153,843
-542,262
-8% -$9.38M ﹤0.01% 1693
2019
Q2 		$119M Hold
6,696,105
– – ﹤0.01% 1659
2019
Q1 		$136M Buy
+6,696,105
New +$135M 0.01% 1575

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group's TAK Position: Q4 2025 in Review

Vanguard Group held its Takeda Pharmaceutical (TAK) position steady in Q4 2025 at 101,870 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3635.

Vanguard Group first reported a position in TAK in Q1 2019 and has held it in 28 quarters since. The position peaked at $136M in Q1 2019. 349 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

  • Vanguard Group held 101,870 shares of Takeda Pharmaceutical worth $1.59M as of Q4 2025.
  • Vanguard Group left its Takeda Pharmaceutical share count unchanged in Q4 2025.
  • Takeda Pharmaceutical made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3635 holding.
  • Vanguard Group first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 28 quarters since.
  • Vanguard Group's Takeda Pharmaceutical position peaked at $136M in Q1 2019.
  • 349 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.